SCHEMBL3306771

SCHEMBL3306771

CCN(CC)C(=O)CCCCC(=O)N(CC)CC

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.89
ALDH1A1 P00352 4/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP3 P08254 1/20 0.46
MMP8 P22894 1/20 0.46
NPC1 O15118 2/20 0.43
TSHR P16473 2/20 0.43
HPGD P15428 2/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
CES2 O00748 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13630657 0.97 LMNA (0.84) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL2479243 0.92 LMNA (0.76) LMNAALDH1A1TSHRALOX15HSD17B10
SCHEMBL782025 0.90 LMNA (0.73) LMNAALDH1A1TSHRALOX15HSD17B10
SCHEMBL781111 0.90 LMNA (0.73) LMNAALDH1A1TSHRALOX15HSD17B10
SCHEMBL780994 0.90 LMNA (0.73) LMNAALDH1A1TSHRALOX15HSD17B10
SCHEMBL23646903 0.90 LMNA (0.73) LMNAALDH1A1TSHRALOX15HSD17B10
SCHEMBL6117074 0.90 LMNA (0.73) LMNAALDH1A1TSHRALOX15HSD17B10
SCHEMBL79816 0.90 LMNA (0.73) LMNAALDH1A1TSHRALOX15HSD17B10
N,N-Diethylstearamide SCHEMBL738376 0.90 LMNA (0.73) LMNAALDH1A1TSHRALOX15HSD17B10
SCHEMBL9570178 0.90 LMNA (0.73) LMNAALDH1A1MMP1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2102148-B1 NOVEL BIS(DIALKYLAMIDE) COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND USES THEREOF RHODIA OPERATIONS (FR) 2015-09-16 EP disclosed
US-8580712-B2 Bis(dialkylamide) compounds and diverse applications thereof RHODIA OPERATIONS (FR) 2013-11-12 US disclosed
US-20130222720-A1 METHOD FOR MANUFACTURING LIQUID CRYSTAL DISPLAY DEVICE PROVIDED WITH FRONT PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE PROVIDED WITH FRONT PLATE KONICA MINOLTA , INC. (JP) 2013-08-29 US disclosed
US-8502937-B2 Protective film for polarizers FUJIFILM CORPORATION (JP) 2013-08-06 US disclosed
US-20100113279-A1 NOVEL BIS(DIALKYLAMIDE) COMPOUNDS AND DIVERSE APPLICATIONS THEREOF SPECIALTY OPERATIONS FRANCE (FR) 2010-05-06 US disclosed
EP-2102148-A1 NOVEL BIS(DIALKYLAMIDE) COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND USES THEREOF Rhodia Opérations (FR) 2009-09-23 EP disclosed
WO-2008074837-A1 NOVEL BIS(DIALKYLAMIDE) COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND USES THEREOF RHODIA OPERATIONS (FR) 2008-06-26 WO disclosed
US-20070259134-A1 Cellulose Compound Film, Optical Compensation Sheet, Polarizing Plate, and Liquid Crystal Display Device FUJIFILM CORPORATION (JP) 2007-11-08 US disclosed
US-20070182895-A1 Liquid crystal display device FUJI PHOTO FILM CO., LTD. (JP) 2007-08-09 US disclosed
CN-1405150-A Protein modifier, preparation method and use thereof PROCESS INST CHINESE ACADEMY O (CN) 2003-03-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113279-A1 NOVEL BIS(DIALKYLAMIDE) COMPOUNDS AND DIVERSE APPLICATIONS THEREOF C1R, CBR3, CWC15 LMNA 187/4885ALDH1A1 3605/4885MMP1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.